Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Copyright 2022, Business Wire.
news
2022-10-20 12:00:00

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ for Injection for the Treatment of Cervical Dystonia
